4/3/2002 - Agilent Technologies Inc. (NYSE: A) today announced a new application for the Agilent 2100 bioanalyzer in conjunction with the DNA 1000 LabChip( kit for the semiquantitation of mRNA expression. The research on the quantitation of mRNA expression was conducted at the Forschungszentrum in Karlsruhe, Germanyand took advantage of comparative multiplex reverse transcription PCR. "Generating data with the Agilent 2100 bioanalyzer is one of the fastest and most robust methods for the analysis of quantitative or semiquantitative PCR applications I have experienced to date," said Dr. Eric Gottwald of the Forschungszentrum in Karlsruhe.
Previous Page | News by Category | News Search
If you found this page useful, bookmark and share it on: